Abstract / Description of output
BACKGROUND & AIMS: Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood.
METHODS: Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls.
RESULTS: Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor.
CONCLUSIONS: We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.
Original language | English |
---|---|
Pages (from-to) | 579-592.e8 |
Journal | Gastroenterology |
Volume | 164 |
Issue number | 4 |
Early online date | 29 Dec 2022 |
DOIs | |
Publication status | Published - Apr 2023 |
Keywords / Materials (for Non-textual outputs)
- Constitutional Mutation Burden
- Functional Test
- Pediatric Cancer
- Replication Error Repair
Access to Document
- 1-s2.0-S0016508522014445-mainFinal published version, 4.59 MBLicence: Creative Commons: Attribution (CC-BY)
Fingerprint
Dive into the research topics of 'Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gastroenterology, Vol. 164, No. 4, 04.2023, p. 579-592.e8.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency
AU - Gallon, Richard
AU - Phelps, Rachel
AU - Hayes, Christine
AU - Brugieres, Laurence
AU - Guerrini-Rousseau, Léa
AU - Colas, Chrystelle
AU - Muleris, Martine
AU - Ryan, Neil A J
AU - Evans, D Gareth
AU - Grice, Hannah
AU - Jessop, Emily
AU - Kunzemann-Martinez, Annabel
AU - Marshall, Lilla
AU - Schamschula, Esther
AU - Oberhuber, Klaus
AU - Azizi, Amedeo A
AU - Baris Feldman, Hagit
AU - Beilken, Andreas
AU - Brauer, Nina
AU - Brozou, Triantafyllia
AU - Dahan, Karin
AU - Demirsoy, Ugur
AU - Florkin, Benoît
AU - Foulkes, William
AU - Januszkiewicz-Lewandowska, Danuta
AU - Jones, Kristi J
AU - Kratz, Christian P
AU - Lobitz, Stephan
AU - Meade, Julia
AU - Nathrath, Michaela
AU - Pander, Hans-Jürgen
AU - Perne, Claudia
AU - Ragab, Iman
AU - Ripperger, Tim
AU - Rosenbaum, Thorsten
AU - Rueda, Daniel
AU - Sarosiek, Tomasz
AU - Sehested, Astrid
AU - Spier, Isabel
AU - Suerink, Manon
AU - Zimmermann, Stefanie-Yvonne
AU - Zschocke, Johannes
AU - Borthwick, Gillian M
AU - Wimmer, Katharina
AU - Burn, John
AU - Jackson, Michael S
AU - Santibanez-Koref, Mauro
N1 - Funding Information: The authors thank all of the patients and their families who provided samples for this study. The authors thank the Genomics Core Facility and Bioinformatics Support Unit, Newcastle University , Newcastle upon Tyne, United Kingdom, for their support of genome and amplicon sequencing, and genome sequence analysis, as well as the research group of Prof Joris Veltman, Newcastle University , Newcastle upon Tyne, United Kingdom, for providing a panel of control blood whole genome sequencing data for variant calling. The authors thank Cancer Research UK for their support through the Aspirin for Cancer Prevention (AsCaP) (C569/A24991) and CaPP (C1297/A15394) groups, and The Barbour Foundation (UK charity 328081). Collection of clinical data and biological samples for French patients was supported by la Fondation Gustave Roussy campaign: Guérir Le Cancer de l’Enfant au 21ème siècle. The study received nonfinancial support from the European Reference Network on genetic tumour risk syndromes (ERN GENTURIS) - Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021”. The authors thank the AsCaP steering committee members for their support: Prof Jack Cuzick, Queen Mary University of London (chair), Prof Frances Balkwill, Queen Mary University of London , Prof Tim Bishop, University of Leeds , Prof Sir John Burn, Newcastle University , Prof Andrew T. Chan, Harvard School of Medicine, Dr Colin Crooks, University of Nottingham, Prof Chris Hawkey, University of Nottingham, Prof Ruth Langley, University College London, Ms Mairead McKenzie, Independent Cancer Patients’ Voice, Dr Belinda Nedjai, Queen Mary University of London, Prof Paola Patrignani, Università G. d'Annunzio di Chieti-Pescara, Prof Carlo Patrono, Catholic University of the Sacred Heart, Rome, Dr Bianca Rocca, Catholic University of the Sacred Heart, Rome, and Dr Samuel Smith, University of Leeds. John Burn is a National Institute for Health and Care Research (NIHR) Senior Investigator and thanks the NIHR for their support. D. Gareth Evans is supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). Funding Information: Funding This study was funded through the Aspirin for Cancer Prevention (AsCaP) group, Cancer Research UK Grant Code: C569/A24991. Cancer Research UK had no role in study design, analysis, or interpretation. The AsCaP group is led by its senior executive board: Prof J. Burn, Prof A. T. Chan, Prof J. Cuzick, Dr B. Nedjai, and Prof Ruth Langley. Funding Information: The authors thank all of the patients and their families who provided samples for this study. The authors thank the Genomics Core Facility and Bioinformatics Support Unit, Newcastle University, Newcastle upon Tyne, United Kingdom, for their support of genome and amplicon sequencing, and genome sequence analysis, as well as the research group of Prof Joris Veltman, Newcastle University, Newcastle upon Tyne, United Kingdom, for providing a panel of control blood whole genome sequencing data for variant calling. The authors thank Cancer Research UK for their support through the Aspirin for Cancer Prevention (AsCaP) (C569/A24991) and CaPP (C1297/A15394) groups, and The Barbour Foundation (UK charity 328081). Collection of clinical data and biological samples for French patients was supported by la Fondation Gustave Roussy campaign: Guérir Le Cancer de l'Enfant au 21ème siècle. The study received nonfinancial support from the European Reference Network on genetic tumour risk syndromes (ERN GENTURIS) - Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021”. The authors thank the AsCaP steering committee members for their support: Prof Jack Cuzick, Queen Mary University of London (chair), Prof Frances Balkwill, Queen Mary University of London, Prof Tim Bishop, University of Leeds, Prof Sir John Burn, Newcastle University, Prof Andrew T. Chan, Harvard School of Medicine, Dr Colin Crooks, University of Nottingham, Prof Chris Hawkey, University of Nottingham, Prof Ruth Langley, University College London, Ms Mairead McKenzie, Independent Cancer Patients’ Voice, Dr Belinda Nedjai, Queen Mary University of London, Prof Paola Patrignani, Università G. d'Annunzio di Chieti-Pescara, Prof Carlo Patrono, Catholic University of the Sacred Heart, Rome, Dr Bianca Rocca, Catholic University of the Sacred Heart, Rome, and Dr Samuel Smith, University of Leeds. John Burn is a National Institute for Health and Care Research (NIHR) Senior Investigator and thanks the NIHR for their support. D. Gareth Evans is supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). Genome sequence BAM and amplicon sequence FASTQ files are available from the European Nucleotide Archive (https://www.ebi.ac.uk/ena/browser/home) using Study IDs PRJEB39601 and PRJEB53321, respectively. Richard Gallon, PhD (Conceptualization: Equal; Data curation: Lead; Formal analysis: Equal; Funding acquisition: Supporting; Investigation: Equal; Methodology: Equal; Software: Equal; Supervision: Equal; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Lead). Rachel Phelps, MSc (Investigation: Supporting; Methodology: Supporting; Writing – review & editing: Supporting). Christine Hayes, BSc (Investigation: Supporting; Methodology: Supporting; Writing – review & editing: Supporting). Laurence Brugieres, MD (Data curation: Supporting; Resources: Equal; Writing – review & editing: Supporting). Léa Guerrini-Rousseau, MD (Data curation: Supporting; Resources: Equal; Writing – review & editing: Supporting). Chrystelle Colas, MD, PhD (Data curation: Supporting; Resources: Equal; Writing – review & editing: Supporting). Martine Muleris, HDR (Data curation: Supporting; Resources: Equal; Writing – review &editing: Supporting). Neil A. J. Ryan, MBChB, PhD (Resources: Equal; Writing – review & editing: Supporting). D. Gareth Evans, MD (Resources: Equal; Writing – review & editing: Supporting). Hannah Grice, BSc (Investigation: Supporting; Writing – review & editing: Supporting). Emily Jessop, BSc (Investigation: Supporting; Writing – review & editing: Supporting). Annabel Kunzemann-Martinez, MSc (Investigation: Supporting; Writing – review & editing: Supporting). Lilla Marshall, BSc (Investigation: Supporting; Writing – review & editing: Supporting). Esther Schamschula, PhD (Data curation: Supporting; Formal analysis: Supporting; Writing – review & editing: Supporting). Klaus Oberhuber, Dipl.MTA (Data curation: Supporting; Resources: Supporting; Writing– review & editing: Supporting). Amedeo A. Azizi, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Hagit Baris Feldman, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Andreas Beilken, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Nina Brauer, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Triantafyllia Brozou, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Karin Dahan, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Ugur Demirsoy, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Benoît Florkin, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). William Foulkes, MBBS, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Danuta Januszkiewicz-Lewandowska, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Kristi J. Jones, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Christian P. Kratz, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Stephan Lobitz, MD, MSc (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Julia Meade, MD (Data curation: Supporting; Resources: Supporting; Writing – review& editing: Supporting). Michaela Nathrath, MD (Data curation: Supporting; Resources: Supporting; Writing –review & editing: Supporting). Hans-Jürgen Pander, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Claudia Perne, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Iman Ragab, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Tim Ripperger, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Thorsten Rosenbaum, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Daniel Rueda, PhD (Data curation: Supporting; Resources: Supporting; Writing –review & editing: Supporting). Tomasz Sarosiek, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Astrid Sehested, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Isabel Spier, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Manon Suerink, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Stefanie-Yvonne Zimmermann, MD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Johannes Zschocke, MD, PhD (Data curation: Supporting; Resources: Supporting; Writing – review & editing: Supporting). Gillian M. Borthwick, PhD (Data curation: Supporting; Funding acquisition: Supporting; Project administration: Equal; Resources: Supporting; Writing – review & editing: Supporting). Katharina Wimmer, PhD (Data curation: Supporting; Formal analysis: Supporting; Resources: Equal; Supervision: Equal; Visualization: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). John Burn, MD (Conceptualization: Equal; Data curation: Supporting; Formal analysis: Supporting; Funding acquisition: Lead; Project administration: Supporting; Resources: Equal; Supervision: Equal; Visualization: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Michael S. Jackson, PhD (Conceptualization: Equal; Data curation: Supporting; Formal analysis: Equal; Funding acquisition: Supporting; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Equal; Visualization: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Mauro Santibanez-Koref, MD (Conceptualization: Equal; Data curation: Supporting; Formal analysis: Equal; Funding acquisition: Supporting; Investigation: Equal; Methodology: Equal; Project administration: Equal; Software: Equal; Supervision: Equal; Visualization: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting). Funding This study was funded through the Aspirin for Cancer Prevention (AsCaP) group, Cancer Research UK Grant Code: C569/A24991. Cancer Research UK had no role in study design, analysis, or interpretation. The AsCaP group is led by its senior executive board: Prof J. Burn, Prof A. T. Chan, Prof J. Cuzick, Dr B. Nedjai, and Prof Ruth Langley. Publisher Copyright: © 2023 The Authors
PY - 2023/4
Y1 - 2023/4
N2 - BACKGROUND & AIMS: Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood.METHODS: Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls.RESULTS: Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor.CONCLUSIONS: We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.
AB - BACKGROUND & AIMS: Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood.METHODS: Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls.RESULTS: Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor.CONCLUSIONS: We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.
KW - Constitutional Mutation Burden
KW - Functional Test
KW - Pediatric Cancer
KW - Replication Error Repair
U2 - 10.1053/j.gastro.2022.12.017
DO - 10.1053/j.gastro.2022.12.017
M3 - Article
C2 - 36586540
SN - 1528-0012
VL - 164
SP - 579-592.e8
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -